p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.

doi:10.1016/j.modpat.2023.100100

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Apr 2023

Mueller Sophie, Grote Isabel, Bartels Stephan, Kandt Leonie, Christgen Henriette, Lehmann Ulrich, Gluz Oleg, Graeser Monika, Kates Ron, Harbeck Nadia, Kreipe Hans, Christgen Matthias

Abstract excerpt

TP53 mutation is associated with primary endocrine resistance in luminal breast cancer (BC). Nuclear accumulation of p53, as determined by immunohistochemistry (IHC), is a surrogate marker for TP53 mutation. The immunohistochemical p53 index that defines a p53-positive status is not well established. This study determined the optimal p53 index cutoff to identify luminal BCs harboring TP53 mutations. In total, 364...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Mutation
Share to Tumor Suppressor Protein p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 36788081
DOI: 10.1016/j.modpat.2023.100100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.